Cargando…
Is empiric proton pump inhibition in patients with symptoms of extraesophageal gastroesophageal reflux justified?
BACKGROUND: The prevalence of gastroesophageal reflux disease (GERD) has had a marked increase in Western countries with a paralleling interest in extraesophageal (EE) manifestations of GERD, including laryngopharyngeal reflux (LPR). There are considerable differences in clinical practice between ga...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483799/ https://www.ncbi.nlm.nih.gov/pubmed/37674110 http://dx.doi.org/10.1186/s12876-023-02945-7 |
_version_ | 1785102461305880576 |
---|---|
author | Fossmark, Reidar Ness-Jensen, Eivind Sørdal, Øystein |
author_facet | Fossmark, Reidar Ness-Jensen, Eivind Sørdal, Øystein |
author_sort | Fossmark, Reidar |
collection | PubMed |
description | BACKGROUND: The prevalence of gastroesophageal reflux disease (GERD) has had a marked increase in Western countries with a paralleling interest in extraesophageal (EE) manifestations of GERD, including laryngopharyngeal reflux (LPR). There are considerable differences in clinical practice between gastroenterologists, otolaryngologists and pulmonologists. METHODS: In this narrative review we address some of these controversies concerning EE manifestations of GERD and LPR. RESULTS: It is disputed whether there is causal relationship between reflux and the numerous symptoms and conditions suggested to be EE manifestations of GERD. Similarly, the pathophysiology is uncertain and there are disagreements concerning diagnostic criteria. Consequently, it is challenging to provide evidence-based treatment recommendations. A significant number of patients are given a trial course with a proton pump inhibitor (PPI) for several months before symptoms are evaluated. In randomized controlled trials (RCTs) and meta-analyses of RCTs PPI treatment does not seem to be advantageous over placebo, and the evidence supporting that patients without verified GERD have any benefit of PPI treatment is negligible. There is a large increase in both over the counter and prescribed PPI use in several countries and a significant proportion of this use is without any symptomatic benefit for the patients. Whereas short-term treatment has few side effects, there is concern about side-effects after long-term use. Although empiric PPI treatment for suspected EE manifestations of GERD instead of prior esophageal 24-hour pH and impedance monitoring is included in several guidelines by various societies, this practice contributes to overtreatment with PPI. CONCLUSION: We argue that the current knowledge suggests that diagnostic testing with pH and impedance monitoring rather than empiric PPI treatment should be chosen in a higher proportion of patients presenting with symptoms possibly attributable to EE reflux. |
format | Online Article Text |
id | pubmed-10483799 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-104837992023-09-08 Is empiric proton pump inhibition in patients with symptoms of extraesophageal gastroesophageal reflux justified? Fossmark, Reidar Ness-Jensen, Eivind Sørdal, Øystein BMC Gastroenterol Review BACKGROUND: The prevalence of gastroesophageal reflux disease (GERD) has had a marked increase in Western countries with a paralleling interest in extraesophageal (EE) manifestations of GERD, including laryngopharyngeal reflux (LPR). There are considerable differences in clinical practice between gastroenterologists, otolaryngologists and pulmonologists. METHODS: In this narrative review we address some of these controversies concerning EE manifestations of GERD and LPR. RESULTS: It is disputed whether there is causal relationship between reflux and the numerous symptoms and conditions suggested to be EE manifestations of GERD. Similarly, the pathophysiology is uncertain and there are disagreements concerning diagnostic criteria. Consequently, it is challenging to provide evidence-based treatment recommendations. A significant number of patients are given a trial course with a proton pump inhibitor (PPI) for several months before symptoms are evaluated. In randomized controlled trials (RCTs) and meta-analyses of RCTs PPI treatment does not seem to be advantageous over placebo, and the evidence supporting that patients without verified GERD have any benefit of PPI treatment is negligible. There is a large increase in both over the counter and prescribed PPI use in several countries and a significant proportion of this use is without any symptomatic benefit for the patients. Whereas short-term treatment has few side effects, there is concern about side-effects after long-term use. Although empiric PPI treatment for suspected EE manifestations of GERD instead of prior esophageal 24-hour pH and impedance monitoring is included in several guidelines by various societies, this practice contributes to overtreatment with PPI. CONCLUSION: We argue that the current knowledge suggests that diagnostic testing with pH and impedance monitoring rather than empiric PPI treatment should be chosen in a higher proportion of patients presenting with symptoms possibly attributable to EE reflux. BioMed Central 2023-09-06 /pmc/articles/PMC10483799/ /pubmed/37674110 http://dx.doi.org/10.1186/s12876-023-02945-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Fossmark, Reidar Ness-Jensen, Eivind Sørdal, Øystein Is empiric proton pump inhibition in patients with symptoms of extraesophageal gastroesophageal reflux justified? |
title | Is empiric proton pump inhibition in patients with symptoms of extraesophageal gastroesophageal reflux justified? |
title_full | Is empiric proton pump inhibition in patients with symptoms of extraesophageal gastroesophageal reflux justified? |
title_fullStr | Is empiric proton pump inhibition in patients with symptoms of extraesophageal gastroesophageal reflux justified? |
title_full_unstemmed | Is empiric proton pump inhibition in patients with symptoms of extraesophageal gastroesophageal reflux justified? |
title_short | Is empiric proton pump inhibition in patients with symptoms of extraesophageal gastroesophageal reflux justified? |
title_sort | is empiric proton pump inhibition in patients with symptoms of extraesophageal gastroesophageal reflux justified? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483799/ https://www.ncbi.nlm.nih.gov/pubmed/37674110 http://dx.doi.org/10.1186/s12876-023-02945-7 |
work_keys_str_mv | AT fossmarkreidar isempiricprotonpumpinhibitioninpatientswithsymptomsofextraesophagealgastroesophagealrefluxjustified AT nessjenseneivind isempiricprotonpumpinhibitioninpatientswithsymptomsofextraesophagealgastroesophagealrefluxjustified AT sørdaløystein isempiricprotonpumpinhibitioninpatientswithsymptomsofextraesophagealgastroesophagealrefluxjustified |